Global Hepatocellular Carcinoma Drugs Market Growth (Status and Outlook) 2023-2029

Global Hepatocellular Carcinoma Drugs Market Growth (Status and Outlook) 2023-2029

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

LPI (LP Information)' newest research report, the “Hepatocellular Carcinoma Drugs Industry Forecast” looks at past sales and reviews total world Hepatocellular Carcinoma Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hepatocellular Carcinoma Drugs sales for 2023 through 2029. With Hepatocellular Carcinoma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatocellular Carcinoma Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hepatocellular Carcinoma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatocellular Carcinoma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatocellular Carcinoma Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatocellular Carcinoma Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatocellular Carcinoma Drugs.

The global Hepatocellular Carcinoma Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

This report presents a comprehensive overview, market shares, and growth opportunities of Hepatocellular Carcinoma Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Brachytherapy
Chemotherapy
Local Ablation Therapy

Segmentation by application
Hospitals
Clinics
Cancer Rehabilitation Centers

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis

Please note: The report will take approximately 2 business days to prepare and deliver.